Tsudome, R. et al. 2025. Anti-Oxidative Effect of Dapagliflozin, a Selective Sodium Glucose Transporter-2 Inhibitor, for Cardio-Renal Protection in Patients With Heart Failure With Reduced Ejection Fraction. Cardiology Research. 16, 6 (Dec. 2025), 489–498. DOI:https://doi.org/10.14740/cr2109.